SCHEMBL347765

SCHEMBL347765

CNCCNCCN(C)CCN

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 3/20 0.39
CARM1 Q86X55 2/20 0.37
PRMT6 Q96LA8 2/20 0.37
PRMT8 Q9NR22 2/20 0.37
PRMT3 O60678 1/20 0.37
PRMT1 Q99873 1/20 0.37
LMNA P02545 2/20 0.36
CA12 O43570 2/20 0.36
CA6 P23280 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
CA5B Q9Y2D0 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
ALOX15 P16050 1/20 0.36
CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377182 1.00 CYP2C9 (0.46) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL5707199 0.91 CYP2C19 (0.58) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL31034335 0.89 CYP2C19 (0.56) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL12026375 0.88 CYP2C9 (0.41) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL16328822 0.88 CYP2C9 (0.37) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL16363716 0.88 CYP2C9 (0.46) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL6131299 0.87 CYP2C19 (0.58) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL31034296 0.86 CYP2C19 (0.62) CYP2C9CYP2C19TDP1CARM1PRMT6
SCHEMBL341302 0.86
SCHEMBL15189352 0.86 PRMT1 (0.50) CYP2C9CYP2C19TDP1CARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016033156-A1 IRON-CATALYZED OXIDATIVE POLYMERIZATION OF PHENOLS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2016-03-03 WO disclosed
US-20120016147-A1 METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed
US-8048982-B2 Method for producing aromatic compound polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-11-01 US disclosed
WO-2011107512-A1 THE USE OF LINEAR TRIETHYLENTETRAMINE AS CURING AGENT FOR EPOXY RESINS BASF SE (DE) 2011-09-09 WO disclosed
WO-2010146009-A1 METHYL-SUBSTITUTED TETA COMPOUNDS BASF SE (DE) 2010-12-23 WO disclosed
EP-2241548-A1 Vanadium di-nuclear complex Sumitomo Chemical Company, Limited (JP) 2010-10-20 EP disclosed
EP-2241547-A1 Method for producing aromatic compound polymer Sumitomo Chemical Company, Limited (JP) 2010-10-20 EP disclosed
US-20090018309-A1 Method for Producing Aromatic Compound Polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-15 US disclosed
EP-1767560-A1 METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER Sumitomo Chemical Company, Limited (JP) 2007-03-28 EP disclosed
EP-1114836-B1 PROCESS FOR PRODUCING A RESIN COMPOSITION NAT INST OF ADVANCED IND SCIEN (JP) 2006-11-08 EP disclosed
EP-1114836-A1 RESIN COMPOSITION AND PROCESS FOR PRODUCING THE SAME Japan as represented by Secretary of Agency of Industrial Science and Technology (JP) 2001-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018309-A1 Method for Producing Aromatic Compound Polymer PAH, MAOA, AHR CYP2C9 166/4885CYP2C19 171/4885TDP1 1286/4885
US-20120016147-A1 METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER PAH, MAOA, AHR CYP2C9 159/4885CYP2C19 173/4885TDP1 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.